Longevity Health Holdings, Inc.: Key Director Resignation Announced
Longevity Health Holdings, Inc. (formerly Carmell Corp, Carmell Therapeutics Corp, and Alpha Healthcare Acquisition Corp III) has filed a Form 8-K dated June 1, 2026, reporting a significant board development that investors should pay close attention to.
Key Points from the SEC Filing
- Director Resignation: On June 1, 2026, Kathryn Gregory notified the Company of her resignation from the Board of Directors. Her departure was effective as of the close of business on June 1, 2026.
- No Disagreements: The filing explicitly states that Ms. Gregory’s resignation was not the result of any disagreement with the Company regarding its operations, policies, or practices.
- Emerging Growth Company Status: Longevity Health Holdings, Inc. is designated as an Emerging Growth Company under SEC rules, which may impact its financial reporting and regulatory requirements.
- No Registered Securities: The company currently has No Securities registered pursuant to Section 12(b) of the Exchange Act.
- Corporate Details:
- Principal office: 2403 Sidney Street, Suite 300, Pittsburgh, PA 15203
- SEC File Number: 001-40228
- EIN: 86-1645738
- State of Incorporation: Delaware
- Filing Status: The Form 8-K is not an amendment and contains no written communications, soliciting material, or tender offer communications.
Potential Shareholder Impact & Price Sensitivity
- Board Change: The resignation of a director—especially if they are perceived as integral to corporate governance, strategy, or investor confidence—can be material to share price movement. However, the company has made clear there is no underlying dispute or disagreement prompting the resignation.
- Governance Considerations: Investors may interpret the change as a routine board turnover, but it is important to monitor subsequent filings for information about a replacement or adjustments to board committees.
- Emerging Growth Company Status: This status allows for scaled disclosure and reduced regulatory costs, which can be favorable for growth but may limit visibility for investors. Shareholders should be aware that Longevity Health Holdings, Inc. has not elected to use the extended transition period for complying with new or revised accounting standards.
- Recent Corporate Name Changes: The company has undergone several name changes in recent years, indicating possible strategic shifts or restructuring. These include transitions from Carmell Corp, Carmell Therapeutics Corp, and Alpha Healthcare Acquisition Corp III.
Additional Details
- Filing Purpose: The report is strictly to inform about the departure of a director, the company’s emerging growth status, and other entity information.
- Signature: The filing is signed by Bryan J. Cassaday, Chief Financial Officer.
What Investors Should Watch Next
- Monitor for any announcements regarding who will fill the vacated board seat, or any changes in board structure.
- Review upcoming quarterly or annual filings for further strategic updates or operational developments.
- Consider implications of the company’s emerging growth status on reporting and transparency.
Disclaimer: This article is based on information from the SEC Form 8-K filed by Longevity Health Holdings, Inc. on June 1, 2026. It is intended for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult professional advisors before making investment decisions. The resignation of a director may not necessarily impact share price unless accompanied by further corporate or strategic developments.
